B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses

B cell–targeted therapies, such as CD20-targeting mAbs, deplete B cells but do not target the autoantibody-producing plasma cells (PCs). PC-targeting therapies such as daratumumab (anti-CD38) form an attractive approach to treat PC-mediated diseases. CD38 possesses enzymatic and receptor capabilitie...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeven, Dorit, Grinwis, Lucas, Marsman, Casper, Jansen, Machiel H, Van Leeuwen, Ester MM, Kuijpers, Taco W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331639/
https://www.ncbi.nlm.nih.gov/pubmed/37419630
http://dx.doi.org/10.26508/lsa.202302214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331639/
https://www.ncbi.nlm.nih.gov/pubmed/37419630
http://dx.doi.org/10.26508/lsa.202302214

Ejemplares similares